Introduction: Social distancing and wearing a face mask are highly recommended to mitigate the transmission of coronavirus disease 2019 (COVID-19). However, the success of these strategies relies on individuals’ adherence and public compliance. This study was conducted to assess the level of belief in social distancing and face mask practices in communities in low- and middle-income countries (LMICs) and to identify their possible determinants. Methods: A cross-sectional study was conducted in ten LMICs countries in Asia, Africa, and South America from February to May 2021. A questionnaire was used to assess the belief, practice, and their plausible determinants. Identification of the associated determinants was performed using a logistic regression model. Results: Our data revealed that only 62.6% and 66.9% of the participants had good beliefs in social distancing and good face mask practices, respectively. Residing in the Americas, having a healthcare-related job, knowing people in immediate social environment who are or have been infected and exposure to information of COVID-19 cases on social media or TV were factors significantly associated with good belief in social distancing. Residing country, gender, monthly household income, type of job and exposure to information of COVID-19 cases were significantly associated with face mask wearing practice. Conclusion: The proportion of participants having good beliefs in social distancing and good face mask practices is relatively low (<75%). Hence, sustained health campaigns regarding social distancing benefits and face mask-wearing practices during COVID-19 are critical in LMICs.
During the preoperative planning of shoulder arthroplasty, the surgeon encounters bone defects of the glenoid in more than 39 % of cases. Ignoring the bone defect of the glenoid leads to the malposition of the glenoidal component of the endoprosthesis, scapular notching, excessive medialization of the center of rotation, which in turn can reduce the strength and leverage of the deltoid muscle. Accurate diagnosis, assessment and selection of the optimal method of bone defect replacement are necessary for the proper functioning of the endoprosthesis and the duration of its service life. Aim of the study was to review the literature data over the past 10 years on reverse shoulder replacement in patients with glenoid bone defects, to consider diagnostic methods, indications, advantages and disadvantages, as well as complications with various methods of restoration of glenoid bone defects. Material and methods. The search for publications from 2014 to 2024 was carried out in databases PubMed, ResearchGate, ScienceDirect upon request: (“glenoid bone loss” OR “glenoid bone deficiency”) and “shoulder arthroplasty”. Results and discussion. The gold standard and mandatory method should be computed tomography examination, which is necessary for three-plane evaluation of the glenoid defect and component positioning planning. The review presents various classifications, however, an universal classification that not only describes the configuration and degree of the defect, but is also directly related to treatment tactics has not been developed at the moment. Various types of defect replacement are considered. The indications, limitations and disadvantages of each method are systematized in the table. Conclusions. Nowadays, the world literature lacks not only large-scale long-term observations and meta-analyses on reverse shoulder arthroplasty for glenoid bone defects, but also comparative studies of different types of treatment for comparable groups, which emphasizes the relevance of conducting new research in this area.
Objective : To evaluate the effectiveness and safety of 177 Lu-PSMA radioligand therapy (RLT) in patients with disseminated prostate cancer who were followed up in healthcare institutions of the Moscow Department of Health and received treatment outside of clinical trials. Materials and methods : This retrospective study included patients with disseminated prostate cancer treated with 177 Lu-PSMA RLT and followed up at outpatient oncology centers in Moscow between January 1, 2022, and December 1, 2025. Inclusion criteria: histologically verified prostate adenocarcinoma, radiological signs of metastatic disease, and treatment with at least 1 cycle of 177 Lu-PSMA RLT. Exclusion criteria: absence of data on ≥ 1 177 Lu-PSMA administration and ≥ 1 follow-up examination after treatment initiation. The primary endpoint was radiologic progression-free survival (rPFS). The secondary endpoints included the PSA50 response rate (defined as a ≥ 50 % decline in prostate-specific antigen from baseline), PSA progression-free survival (PSA-PFS), progression-free survival according to the Prostate Cancer Working Group 3 criteria (PFSPCWG3), overall survival (OS), time to clinical deterioration, safety, and toxicity. Results : A total of 41 patients were included in the analysis. The median age was 72 years (range: 53–85). At RLT initiation (baseline), 9 patients (21.9 %) had ECOG PS scores of 2–3. Twenty-nine patients (70.7 %) had been previously treated with ≥ 1 taxane and ≥ 1 androgen receptor signaling inhibitor (ARSI). Castration resistance prior to RLT initiation was observed in 40 patients (97.6 %). The median baseline PSA level was 121.7 ng / mL (range: 0.6–4987.7). All patients had PSMA-positive metastases; in 3 cases (7.3 %), these were accompanied by clinically significant PSMA-negative metastases. All patients received 177 Lu-PSMA RLT (median of 4 cycles [range, 1–8]). Forty patients (97.6 %) received RLT concomitantly with continuous androgen deprivation therapy (ADT); 11 patients (26.8 %) received RLT during ADT in combination with an ARSI; 3 patients (7.3 %) underwent combined systemic radiopharmaceutical therapy (2 patients [4.9 %] with 177 Lu-PSMA / 153 Sm, and 1 patient [2.4 %] with 177 Lu-PSMA / 225 Ac-PSMA). The median follow-up duration was 10 months (range: 0.4–30). The PSA50 response rate was 46.3 %, median rPFS was 6.2 months (95 % confidence interval [CI], 4.7–7.7), median PSA-PFS was 5.2 months (95 % CI, 2.7–7.7), median PFSPCWG3 was 5.7 months (95 % CI, 4.8–6.5), median OS was 11.4 months (95 % CI, 6.2–16.6), and median time to clinical deterioration was 5.8 months (95 % CI, 3.9–7.8). Serious AEs were reported in 18 patients (43.9 %), AE-related RLT discontinuation was required in 8 cases (19.5 %), and AE-related death was reported in 3 cases (7.3 %). Grade 3–4 anemia developed in 15 patients (36.6 %), grade 3–4 thrombocytopenia in 14 patients (34.1 %), and neutropenia in 17 patients (41.5 %). Conclusion : Data from real-world clinical practice confirm the effectiveness of 177 Lu-PSMA RLT in patients with disseminated prostate cancer. However, the safety profile raises significant concern. These findings highlight the need for a more balanced approach to patient selection for RLT.
The paper presents a clinical case of appendiceal mucinous adenocarcinoma with invasion into the right ovary, imitating an ovarian tumor. The primary tumor was diagnosed only after a pathological evaluation of the surgical material with differential immunohistochemical assay after laparotomy and removal of the ovarian tumor and appendectomy. Difficulties in establishing an accurate diagnosis were caused by extensive invasion of the appendiceal tumor into the ovary. This disease requires increased oncological alertness and a clear algorithm for differential diagnosis of mucinous tumors of the appendix and ovary.
The Russian consensus on prevention, diagnostic and treatment of gastric cancer was prepared on the initiative of the Moscow clinical scientific center named after A. S. Loginov on the Delphi method. Its aim was to clarify and consolidate the opinions of specialists on the most relevant issues of prevention, diagnosis and treatment of gastric cancer. An interdisciplinary approach was provided by the participation of leading gastroenterologists, oncologists and surgeons.
